RGDXQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RGDXQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Response Genetics's accounts receivables for the quarter that ended in Mar. 2015 was $6.06 Mil.
Accounts receivable can be measured by Days Sales Outstanding. Response Genetics's Days Sales Outstanding for the quarter that ended in Mar. 2015 was 145.84.
In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Response Genetics's Net-Net Working Capital per share for the quarter that ended in Mar. 2015 was $-0.24.
The historical data trend for Response Genetics's Accounts Receivable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Response Genetics Annual Data | |||||||||||||||||||||
Trend | Dec06 | Dec07 | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | |||||||||||
Accounts Receivable | Get a 7-Day Free Trial |
![]() |
![]() |
4.05 | 5.37 | 6.23 | 5.03 | 6.62 |
Response Genetics Quarterly Data | ||||||||||||||||||||
Sep10 | Dec10 | Mar11 | Jun11 | Sep11 | Dec11 | Mar12 | Jun12 | Sep12 | Dec12 | Mar13 | Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Dec15 | |
Accounts Receivable | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
6.53 | 6.89 | 5.03 | 6.06 | 6.62 |
Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.
Response Genetics's Days Sales Outstanding for the quarter that ended in Mar. 2015 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 6.059 | / | 3.791 | * | 91 |
= | 145.84 |
2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Response Genetics's accounts receivable are only considered to be worth 75% of book value:
Response Genetics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2015 is calculated as:
Net-Net Working Capital Per Share | |||||||
= | (Cash And Cash Equivalents | + | 0.75 * Accounts Receivable | + | 0.5 * Total Inventories | - | Total Liabilities |
- | Preferred Stock | - | Minority Interest) | / | Shares Outstanding (EOP) | ||
= | (1.735 | + | 0.75 * 6.059 | + | 0.5 * 0 | - | 15.715 |
- | 0 | - | 0) | / | 38.7954 | ||
= | -0.24 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.
If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.
Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.
Thank you for viewing the detailed overview of Response Genetics's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.
Roberto Mignone | 10 percent owner | C/O BRIDGER MANAGEMENT, LLC., 90 PARK AVENUE, 40TH FL., NEW YORK NY 10016 |
Bridger Management Llc | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Swiftcurrent Offshore Ltd | 10 percent owner | C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, PO BOX 309, GRAND CAYMAN E9 KY1-1104 |
David Schreiber | director | 15 TROTTERS LANE, MONROE CT 06468 |
Sam Chawla | director | 1640 MARENGO STREET, 6TH FLOOR, LOS ANGELES CA 90033 |
Van Den Broek Richard | director | 73 ARCH STREET, 1ST FLOOR, GREENWICH CT 06830 |
Kevin Roy Harris | officer: Vice President and CFO | 345 N MAPLE DRIVE, SUITE 120, BEVERLY HILLS CA 90210 |
Kirk K Calhoun | director | 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054 |
Michael Serruya | director | C/O RESPONSE GENETICS, INC., 1640 MARENGO ST., 6TH FLOOR, LOS ANGELES CA 90033 |
Thomas A Bologna | director, officer: Chief Executive Officer | 4390 US ROUTE ONE, PRINCETON NJ 08540 |
Marxe Austin W & Greenhouse David M | 10 percent owner | C/O SPECIAL SITUATIONS FUNDS, 527 MADISON AVENUE, SUITE 2600, NEW YORK NY 10022 |
Partners Swiftcurrent | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Bridger Capital Llc | 10 percent owner | 90 PARK AVENUE, 40TH FLOOR, NEW YORK NY 10016 |
Plc Glaxosmithkline | 10 percent owner | 980 GREAT WEST ROAD, BRENTFORD MIDDLESEX X0 TW8 9GS |
Michael A Metzger | director | C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451 |
From GuruFocus
By gurufocus • 05-15-2009
By GuruFocus Research GuruFocus Editor • 12-14-2009
By gurufocus 10qk • 11-09-2010
By gurufocus 10qk • 08-22-2009
By gurufocus 10qk • 05-14-2010
By gurufocus 10qk • 11-16-2009
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.